Belen Ponte1, Menno Pruijm2, Daniel Ackermann3, Georg Ehret4, Nicolas Ansermot5, Jan A Staessen6, Bruno Vogt3, Antoinette Pechère-Bertschi7, Michel Burnier2, Pierre-Yves Martin8, Chin B Eap9, Murielle Bochud10, Idris Guessous11. 1. Service of Nephrology, Department of Specialties, University Hospital of Geneva, Switzerland; Division of Chronic Diseases, Institute of Social and Preventive Medicine (IUMSP), University Hospital of Lausanne, Switzerland. 2. Service of Nephrology, University Hospital of Lausanne, Switzerland. 3. Clinic for Nephrology, Hypertension and Clinical Pharmacology, Inselspital, Bern University Hospital and University of Bern, Switzerland. 4. Department of Cardiology, University Hospital of Geneva, Switzerland. 5. Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neurosciences, Department of Psychiatry, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Hospital of Cery, Prilly, Switzerland. 6. Studies Coordinating Centre, Division of Hypertension and Cardiovascular Rehabilitation, Department of Cardiovascular Diseases, University of Leuven, Belgium; Department of Epidemiology, Maastricht University, the Netherlands. 7. Unit of Hypertension, Department of Community Medicine and Primary Care and Emergency Medicine, University Hospital of Geneva, Switzerland. 8. Service of Nephrology, Department of Specialties, University Hospital of Geneva, Switzerland. 9. Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neurosciences, Department of Psychiatry, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Hospital of Cery, Prilly, Switzerland; School of Pharmacy Geneva-Lausanne, Universities of Geneva and Lausanne, Switzerland. 10. Division of Chronic Diseases, Institute of Social and Preventive Medicine (IUMSP), University Hospital of Lausanne, Switzerland. 11. Unit of Population Epidemiology, Department of Community Medicine and Primary Care and Emergency Medicine, University Hospital of Geneva, Switzerland; Division of Chronic Diseases, Institute of Social and Preventive Medicine (IUMSP), University Hospital of Lausanne, Switzerland. Electronic address: idris.guessous@hcuge.ch.
Abstract
OBJECTIVE: To assess the influence of caffeine on arterial stiffness by exploring the association of urinary excretion of caffeine and its related metabolites with pulse pressure (PP) and pulse wave velocity (PWV). PARTICIPANTS AND METHODS: Families were randomly selected from the general population of 3 Swiss cities from November 25, 2009, through April 4, 2013. Pulse pressure was defined as the difference between the systolic and diastolic blood pressures obtained by 24-hour ambulatory monitoring. Carotid-femoral PWV was determined by applanation tonometry. Urinary caffeine, paraxanthine, theophylline, and theobromine excretions were measured in 24-hour urine collections. Multivariate linear and logistic mixed models were used to explore the associations of quartiles of urinary caffeine and metabolite excretions with PP, high PP, and PWV. RESULTS: We included 863 participants with a mean ± SD age of 47.1±17.6 years, 24-hour PP of 41.9±9.2 mm Hg, and PWV of 8.0±2.3 m/s. Mean (SE) brachial PP decreased from 43.5 (0.5) to 40.5 (0.6) mm Hg from the lowest to the highest quartiles of 24-hour urinary caffeine excretion (P<.001). The odds ratio (95% CI) of high PP decreased linearly from 1.0 to 0.52 (0.31-0.89), 0.38 (0.22-0.65), and 0.31 (0.18-0.55) from the lowest to the highest quartile of 24-hour urinary caffeine excretion (P<.001). Mean (SE) PWV in the highest caffeine excretion quartile was significantly lower than in the lowest quartile (7.8 [0.1] vs 8.1 [0.1] m/s; P=.03). Similar associations were found for paraxanthine and theophylline, whereas no associations were found with theobromine. CONCLUSION: Urinary caffeine, paraxanthine, and theophylline excretions were associated with decreased parameters of arterial stiffness, suggesting a protective effect of caffeine intake beyond its blood pressure-lowering effect.
OBJECTIVE: To assess the influence of caffeine on arterial stiffness by exploring the association of urinary excretion of caffeine and its related metabolites with pulse pressure (PP) and pulse wave velocity (PWV). PARTICIPANTS AND METHODS: Families were randomly selected from the general population of 3 Swiss cities from November 25, 2009, through April 4, 2013. Pulse pressure was defined as the difference between the systolic and diastolic blood pressures obtained by 24-hour ambulatory monitoring. Carotid-femoral PWV was determined by applanation tonometry. Urinary caffeine, paraxanthine, theophylline, and theobromine excretions were measured in 24-hour urine collections. Multivariate linear and logistic mixed models were used to explore the associations of quartiles of urinary caffeine and metabolite excretions with PP, high PP, and PWV. RESULTS: We included 863 participants with a mean ± SD age of 47.1±17.6 years, 24-hour PP of 41.9±9.2 mm Hg, and PWV of 8.0±2.3 m/s. Mean (SE) brachial PP decreased from 43.5 (0.5) to 40.5 (0.6) mm Hg from the lowest to the highest quartiles of 24-hour urinary caffeine excretion (P<.001). The odds ratio (95% CI) of high PP decreased linearly from 1.0 to 0.52 (0.31-0.89), 0.38 (0.22-0.65), and 0.31 (0.18-0.55) from the lowest to the highest quartile of 24-hour urinary caffeine excretion (P<.001). Mean (SE) PWV in the highest caffeine excretion quartile was significantly lower than in the lowest quartile (7.8 [0.1] vs 8.1 [0.1] m/s; P=.03). Similar associations were found for paraxanthine and theophylline, whereas no associations were found with theobromine. CONCLUSION: Urinary caffeine, paraxanthine, and theophylline excretions were associated with decreased parameters of arterial stiffness, suggesting a protective effect of caffeine intake beyond its blood pressure-lowering effect.
Authors: Aurélie Delacrétaz; Frederik Vandenberghe; Anaïs Glatard; Axel Levier; Céline Dubath; Nicolas Ansermot; Séverine Crettol; Mehdi Gholam-Rezaee; Idris Guessous; Murielle Bochud; Armin von Gunten; Philippe Conus; Chin B Eap Journal: Front Psychiatry Date: 2018-11-09 Impact factor: 4.157